AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Jul 2017 03:45 PM
RNS
Holding(s) in Company
03 Jul 2017 02:59 PM
RNS
Total Voting Rights
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
03 Jul 2017 07:00 AM
RNS
AZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23 Jun 2017 12:46 PM
RNS
Faslodex CHMP positive opinion in 1L breast cancer
07 Jun 2017 07:13 AM
RNS
AZ agreement with Grünenthal for rights to Zomig
06 Jun 2017 07:00 AM
RNS
ASTRAZENECA PRICES A $2BN BOND ISSUE
05 Jun 2017 07:00 AM
RNS
LYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
01 Jun 2017 03:00 PM
RNS
Block listing Interim Review
01 Jun 2017 03:00 PM
RNS
Total Voting Rights
31 May 2017 07:00 AM
RNS
Directorate Change
24 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
23 May 2017 07:00 AM
RNS
Bydureon EXSCEL trial meets T2D safety objective
22 May 2017 07:00 AM
RNS
AZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16 May 2017 03:00 PM
RNS
Director/PDMR Shareholding
12 May 2017 07:00 AM
RNS
IMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10 May 2017 07:00 AM
RNS
AZ updates on tralokinumab trial in severe asthma
02 May 2017 02:00 PM
RNS
Total Voting Rights
02 May 2017 07:00 AM
RNS
DURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27 Apr 2017 05:30 PM
RNS
Result of AGM
27 Apr 2017 07:00 AM
RNS
AstraZeneca: Q1 2017 Results
25 Apr 2017 01:30 PM
RNS
TAGRISSO RECEIVES FULL APPROVAL IN THE EU
03 Apr 2017 03:00 PM
RNS
Total Voting Rights
31 Mar 2017 07:01 AM
RNS
Tagrisso (osimertinib) receives FDA full approval
31 Mar 2017 07:00 AM
RNS
AZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28 Mar 2017 04:00 PM
RNS
Director/PDMR Shareholding
27 Mar 2017 03:00 PM
RNS
Director/PDMR Shareholding
17 Mar 2017 07:00 AM
RNS
US FDA issues CRL for ZS-9 in hyperkalaemia
16 Mar 2017 11:00 AM
RNS
Notice of AGM
15 Mar 2017 07:00 AM
RNS
LYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
08 Mar 2017 07:00 AM
RNS
Filing of Form 20-F with SEC
07 Mar 2017 02:30 PM
RNS
Annual Financial Report
06 Mar 2017 07:00 AM
RNS
Directorate Change
03 Mar 2017 07:00 AM
RNS
ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
01 Mar 2017 04:30 PM
RNS
Total Voting Rights
28 Feb 2017 07:02 AM
RNS
FDA approves once-daily Qtern for type-2 diabetes
24 Feb 2017 12:32 PM
RNS
CHMP positive opinion for ZS-9 in hyperkalaemia
20 Feb 2017 07:00 AM
RNS
AZ licenses Zoladex to TerSera for the US & Canada
17 Feb 2017 07:00 AM
RNS
Lynparza positive in metastatic BRCA breast cancer
16 Feb 2017 12:01 PM
RNS
SILIQ (BRODALUMAB) APPROVED BY US FDA
02 Feb 2017 07:00 AM
RNS
AZN: FY16 and Q4 2016 Results
01 Feb 2017 04:00 PM
RNS
Total Voting Rights
26 Jan 2017 10:00 AM
RNS
SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17 Jan 2017 07:00 AM
RNS
AZ 1st-line lung cancer immuno-oncology programme
03 Jan 2017 04:00 PM
RNS
Total Voting Rights
23 Dec 2016 07:00 AM
RNS
AZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16 Dec 2016 01:00 PM
RNS
Director/PDMR Shareholding
09 Dec 2016 03:05 PM
RNS
FDA accepts durvalumab for BLA in bladder cancer
06 Dec 2016 09:30 AM
RNS
Tagrisso data shows superiority over chemotherapy
05 Dec 2016 07:00 AM
RNS
AZ completes agreement for Rhinocort Aqua rights

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings